Member Spotlight: Q&A with Coeus Consulting Group

Aug 03, 2020

Every month, MassBio spotlights a member company and the great work they’re doing to advance the life sciences industry and support the patients we serve. In August, we spoke with Marc Hixson, President & CEO of Coeus Consulting Group. Marc began his life sciences career on the commercial side of the business in sales and marketing, realizing early on that the ever-changing managed care environment would have a greater impact on the way pharmaceutical products and medical services were delivered. Gaining knowledge and insight through experience, he has directed his efforts to the successful creation and execution of multiple market access strategies and teams for various clients.

Tell us about your organization, its mission, and current initiatives.

Founded in 2009, Coeus Consulting Group is a boutique life sciences market access strategy consulting firm offering clients commercial support across the entire development spectrum. Our market access practice works with clients to develop their managed care and pricing and contracting strategy, market access insight generation, HEOR strategy and tactics, launch readiness, account management, operational support, patient access, distribution, and trade and advocacy/policy work. It is our mission to work with clients to show true value of their products to all stakeholders in the healthcare ecosystem to ensure that every patient has access to the therapies they need. 

How does your organization’s activities help patients now and into the future?

Defining value is key to keeping the healthcare ecosystem healthy and viable, Coeus works with all stakeholders to ensure that products are appropriately available to patients when they need them. As cell and gene therapies become the next medical frontier, innovation is needed around the distribution, payment and patient support models that currently exist today. 

What do you see as the biggest challenge facing the life sciences industry today?

The COVID-19 pandemic has changed the ways in which manufacturers engage with their patients, HCPs and payers, however, there seems to still be a large gap between manufacturers and the stakeholders they engage with. Going forward, the new normal will entail utilizing the various data sources they have access to, which may have been previously unavailable, and will be key towards closing those gaps and obtaining reimbursement for their products.

What’s next for your organization / what are you focused on in the coming year?

Our 3rd party adjudication platform for value and/or outcome-based agreements, Coeus Healthcare is starting to expand rapidly and we’ve just completed a merger with Mirador Global who enhances our current offerings and expands them outside the US. Later this year we have plans to offer additional services in the agency space under our Coeus Holdings umbrella of companies. It is our pledge to continue to innovate on behalf of our life science clients to ensure a healthy healthcare ecosystem.

If you’re interested in being featured in MassBio’s Member Spotlight, please see guidelines here.

See all MassBio News